Update on oxerutin, O-(β-hydroxyethyl)-rutosides from established evidence to recent findings

Oxerutin is a phlebotrophic drug with documented effects on capillary permeability and edema, that has been used for many years in the treatment of edema, chronic venous insufficiency (CVI), and diabetic microangiopathy. Treatment with oxerutin has been demonstrated to be effective in improving venous insufficiency symptoms, and in reducing ankle swelling and capillary filtration rate in patients with venous insufficiency and associated venous conditions. In addition, it has been shown to significantly improve microcirculation in patients with diabetic microangiopathy and neuropathy. Studies have also demonstrated that oxerutin is very effective in improving and preserving the quality of life in patients with CVI and venous microangiopathy. Finally, there is a large body of data confirming the safety and tolerability of long-term treatment with oxerutin. In summary, current evidence supports the efficacy, safety, tolerability, and ease of use of oxerutin, administered both systemically and locally, in the treatment of venous disorders and other important conditions as well.